AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III...
Lee’s Pharmaceutical’s Socazolimab Becomes China’s First PD-L1 mAb for Cervical Cancer
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for...
Zhiyi Biotechnology and Henlius Biotech Partner to Develop Novel Drug Products and Platforms
Guangzhou-based Zhiyi Biotechnology has entered into a strategic partnership with Shanghai Henlius Biotech Inc. (HKG:...
FDA Rejects MSD’s Gefapixant for Chronic Cough Treatment Over Efficacy Concerns
The US Food and Drug Administration (FDA) has declined to approve a filing from Merck,...
Shanghai Novopathway and PONY Biomedicine Join Forces for Pre-Clinical Drug Development Platform
Shanghai Novopathway Biotechnology, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow...
GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal
GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing...
3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension
3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a...
Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome
RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...
Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines
Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an...
LianBio Board Turns Down Concentra Biosciences Buyout Offer
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not...
Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal
Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate...
Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement
China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics,...
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese...
RemeGen Ltd Receives FDA Clearance for MSLN-Targeting ADC RC88 in Gynecological Tumors
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical clearance...
China Announces New Hospital Inspection Measures to Standardize Healthcare System
The National Health Commission (NHC), in collaboration with the National Administration of Traditional Chinese Medicine...
MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers
US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership...
Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma
Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors...
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service...